# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $12 price target.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focus...
Broad coverage extended to Japan and related regionsSAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (...
Anixa Biosciences Inc (NASDAQ: ANIX) announced new and updated results from the Phase 1 trial of its breast cancer vaccine.
HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $12 price target.